Company: PCRX
Filing Date: 2025-02-27
Form Type: 10-K
Source: 0001396814-25-000041
Chunk: 99

Company: Pacira BioSciences, Inc.
Filing Date: 2025-02-27
Form: 10-K
Item: Item 8
Chunk 99
---
, 2024

INDEX TO THE CONSOLIDATED FINANCIAL STATEMENTSPage #Report of Independent Registered Public Accounting FirmF-2Auditor Name:KPMG LLPAuditor Location:Short Hills, NJAuditor Firm ID:185Consolidated Balance Sheets as of December 31, 2024 and 2023F-4Consolidated Statements of Operations for the years ended December 31, 2024, 2023 and 2022F-5Consolidated Statements of Comprehensive (Loss) Income for the years ended December 31, 2024, 2023 and 2022F-6Consolidated Statements of Stockholders’ Equity for the years ended December 31, 2024, 2023 and 2022F-7Consolidated Statements of Cash Flows for the years ended December 31, 2024, 2023 and 2022F-8Notes to Consolidated Financial StatementsF-10

Pacira BioSciences, Inc.  |  2024 Annual Report on Form 10-K  |  Page F-1

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Stockholders and Board of Directors

Pacira BioSciences, Inc.:

Opinions on the Consolidated Financial Statements and Internal Control Over Financial Reporting

We have audited the accompanying consolidated balance sheets of Pacira BioSciences, Inc. and subsidiaries (the Company) as of December 31, 2024 and 2023, the related consolidated statements of operations, comprehensive (loss) income, stockholders’ equity, and cash flows for each of the years in the three-year period ended December 31, 2024, and the related notes (collectively, the consolidated financial statements). We also have audited the Company’s internal control over financial reporting as of December 31, 2024, based on criteria established in Internal Control – Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission.

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the years in the three-year period ended December 31, 2024, in conformity with U.S. generally accepted accounting principles. Also in our opinion, the Company maintained,